Avanos Medical, INC Form 4 insider transactions
NYSE
Sigfrido Delgado, SVP of Operations at Avanos Medical, reports acquiring 16,300 shares of common stock and discloses holdings of 44,119 shares following the transaction.
NYSE
Mojirade James, SVP and General Counsel of Avanos Medical, Inc., was granted 16,300 time-based restricted share units (TRSUs) on April 22, 2025, which will vest on April 22, 2026.
NYSE
Form 4: Avanos Medical SVP, General Counsel Mojirade James Reports Acquisition of Shares and Stock Options
Mojirade James, SVP, General Counsel of Avanos Medical, reports the acquisition of restricted share units and stock options.
NYSE
John Hurley, Principal Accounting Officer of Avanos Medical, reports acquiring 1,961 shares of common stock through time-based restricted share units.
NYSE
Kerr Holbrook, SVP, Chief Commercial Officer of Avanos Medical, reports acquisition of restricted share units and employee stock options.
NYSE
Interim CEO of Avanos Medical, Michael Greiner, reports acquisition of common stock and stock options.
NYSE
Form 4: Avanos Medical SVP, Operations, Sigfrido Delgado, Reports Acquisition and Disposal of Shares
Sigfrido Delgado, SVP of Operations at Avanos Medical, reports acquiring shares through restricted stock units and disposing of shares, along with acquiring employee stock options.
NYSE
Michael Greiner, Interim CEO of Avanos Medical, reports disposing of shares to cover tax obligations related to vesting restricted share units.
NYSE
Kerr Holbrook, SVP and Chief Commercial Officer of Avanos Medical, reports the sale of shares to cover tax obligations upon vesting of restricted stock units.
NYSE
Mojirade James, SVP and General Counsel of Avanos Medical, reports disposing of shares to cover tax obligations following the vesting of restricted stock units.
NYSE
John Hurley, Principal Accounting Officer of Avanos Medical, reports disposition of shares to cover tax obligations upon vesting of restricted stock units.
NYSE
Former Avanos Medical CEO, Woody Joseph Fralin, reports disposing of shares to cover tax obligations upon the vesting of restricted share units.
NYSE
A Form 4 filing reveals that Mojirade James, SVP and General Counsel of Avanos Medical, Inc., executed transactions involving common stock and performance-based restricted share units (PRSUs) on March 4, 2025.
NYSE
Former Avanos Medical CEO Joseph Fralin Woody reports the vesting of restricted share units and subsequent transactions to cover tax obligations.
NYSE
A Form 4 filing reveals that Avanos Medical's SVP, Chief Commercial Officer Kerr Holbrook, engaged in transactions involving common stock following the vesting of performance-based and time-based restricted share units.
NYSE
Form 4: Avanos Medical Executive Reports Stock Transactions Following Vesting of Restricted Share Units
John Joseph Hurley, Principal Accounting Officer of Avanos Medical, reports the vesting of performance-based and time-based restricted share units and subsequent transactions to cover tax obligations.
NYSE
Interim CEO Michael Greiner reports the vesting and subsequent transactions of performance-based and time-based restricted share units, along with tax withholding obligations.
NYSE
Form 4: Avanos Medical Director Gary Blackford Acquires 12,003 Shares Through Restricted Stock Units
Director Gary Blackford acquired 12,003 shares of Avanos Medical stock through restricted stock units on January 2, 2025.
NYSE
Form 4: Avanos Medical Director Lisa Egbuonu-Davis Acquires 12,003 Shares Through Restricted Stock Units
Director Lisa Egbuonu-Davis acquired 12,003 shares of Avanos Medical, Inc. through restricted stock units on January 2, 2025.
NYSE
Director Indrani Franchini acquired 12,003 shares of Avanos Medical, Inc. through restricted stock units on January 2, 2025.
NYSE
Form 4: Avanos Medical Director Patrick J. O'Leary Acquires 12,003 Shares Through Restricted Stock Units
Director Patrick J. O'Leary acquired 12,003 shares of Avanos Medical, Inc. through restricted stock units on January 2, 2025.
NYSE
Director Julie Shimer acquired 12,003 shares of Avanos Medical, Inc. through restricted stock units on January 2, 2025.
NYSE
Form 4: Avanos Medical Interim CEO Michael Greiner Acquires 10,000 Shares Through Restricted Stock Units
Avanos Medical's Interim CEO, Michael Greiner, acquired 10,000 shares of common stock through the vesting of time-based restricted stock units.
NYSE
Interim CEO Michael Greiner reports acquiring and disposing of Avanos Medical common stock, including time-based restricted share units (TRSUs).
NYSE
Principal Accounting Officer John Joseph Hurley reports the acquisition of 3,001 restricted share units in Avanos Medical, Inc.
NYSE
A Form 4 filing reveals that Mojirade James, SVP and General Counsel of Avanos Medical, Inc., surrendered shares to cover tax obligations upon vesting of restricted stock units.
NYSE
Michael Greiner, SVP and CFO of Avanos Medical, reports the vesting of performance-based and time-based restricted share units and subsequent transactions to cover tax obligations.
NYSE
SVP, Chief Commercial Officer of Avanos Medical, Kerr Holbrook, reports vesting of restricted share units and subsequent tax withholding.
NYSE
CEO Joseph Woody reports the vesting of performance-based and time-based restricted share units, followed by the surrender of shares to cover tax obligations.
NYSE
Michael Greiner, SVP and CFO of Avanos Medical, sold 8,000 shares of common stock on March 14, 2024, to cover tax obligations from vested restricted share units.